Earth Science Tech, Inc. (OTC: ETST) today announced a series of strategic initiatives aimed at enhancing transparency, governance and alignment with long-term shareholder value as it advances toward becoming a fully institutional-ready public company. The company reported approximately $3.3 million in net income for fiscal 2025 and anticipates $1.4 million in cost savings in fiscal 2026, providing a strong foundation for the planned changes.
Among the key initiatives, the company outlined plans to optimize its portfolio through potential divestitures and brand consolidation. This move is designed to streamline operations and focus on core business areas. Additionally, Earth Science Tech will introduce advisory shareholder votes on executive compensation and the retirement of Series B Preferred Stock, giving shareholders a greater voice in corporate governance. The company also plans to rationalize its capital structure and reduce executive and board compensation, positioning itself for disciplined growth and improved operating leverage.
These governance and capital structure reforms are critical as Earth Science Tech seeks to attract institutional investors, who often require higher standards of transparency and shareholder rights. The company's strong financial performance—with net income of $3.3 million in fiscal 2025 and anticipated cost savings of $1.4 million in fiscal 2026—demonstrates its operational strength and ability to generate value. By reducing compensation and optimizing its portfolio, the company aims to enhance shareholder returns and align management interests with long-term value creation.
The initiatives come at a time when many small-cap companies are striving to meet institutional standards. Earth Science Tech's proactive approach may set a precedent for similar firms looking to attract larger investors. The company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries, including RxCompoundStore.com, LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC, and others. The company also holds an 80% interest in MagneChef.
For more information on the full press release, visit https://ibn.fm/pNJIc. The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST.
